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Introduction
In 1971, Alfred Knudson studied a series of cases of ret-
inoblastoma, a childhood- onset ocular tumor, and pro-
posed the “two- hit- model” [1]. According to this model, 
retinoblastoma is caused by biallelic inactivation of a single 
gene, retinoblastoma1 (RB1). These two “hits” or muta-
tions originally defined the concept of “tumor suppressor” 
genes. In heritable cases of retinoblastoma, the first hit 
is an inherited germline mutation, whereas the second 
hit is a somatic mutation; in sporadic cases, both hits 
are somatic in origin in a single retinal cell which initi-
ates tumorigenesis [1].
Recently, a small subset of retinoblastoma with no 
detectable mutation in RB1, and amplification of the 
MYCN gene was identified [2]. It was hypothesized that 
MYCN amplification initiated retinoblastoma tumorigen-
esis in the presence of functional pRb protein [2].
It is known that pRb can be inactivated by various 
mechanisms including genetic mutations and phosphoryla-
tion [3]. To define which of the identified mechanisms 
is present in MYCN- amplified retinoblastoma, we first 
investigated MYCN copy number and the mutations pre-
sent in RB1 in a series of 245 cases of unilateral retino-
blastoma. We compared and contrasted the clinical features 
of the two groups of tumors classified by their MYCN 
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Abstract
A small, but unique subgroup of retinoblastoma has been identified with no 
detectable mutation in the retinoblastoma gene (RB1) and with high levels of 
MYCN gene amplification. This manuscript investigated alternate pathways of 
inactivating pRb, the encoded protein in these tumors. We analyzed the muta-
tion status of the RB1 gene and MYCN copy number in a series of 245 unilateral 
retinoblastomas, and the phosphorylation status of pRb in a subset of five 
tumors using immunohistochemistry. There were 203 tumors with two muta-
tions in RB1 (RB1−/−, 83%), 29 with one (RB1+/−, 12%) and 13 with no detect-
able mutations (RB1+/+, 5%). Eighteen tumors carried MYCN amplification 
between 29 and 110 copies: 12 had two (RB1−/−) or one RB1 (RB1+/−) mutations, 
while six had no mutations (RB1+/+). Immunohistochemical staining of tumor 
sections with antibodies against pRb and phosphorylated Rb (ppRb) displayed 
high levels of pRb and ppRb in both RB1+/+ and RB1+/− tumors with MYCN 
amplification compared to no expression of these proteins in a classic RB1−/−, 
MYCN- low tumor. These results establish that high MYCN amplification can 
be present in retinoblastoma with or without coding sequence mutations in the 
RB1 gene. The functional state of pRb is inferred to be inactive due to phos-
phorylation of pRb in the MYCN-amplified retinoblastoma without coding 
sequence mutations. This makes inactivation of RB1 by gene mutation or its 
protein product, pRb, by protein phosphorylation, a necessary condition for 
initiating retinoblastoma tumorigenesis, independent of MYCN amplification.
Cancer Medicine
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amplification status. To explore the possibility of pRb 
inactivation by phosphorylation as an alternate pathway, 
we used immunohistochemical staining to evaluate the 
expression of four proteins: SKP2, a target of MYCN 
amplification, p27, a substrate for SKP2 ubiquitination 
thereby inhibiting pRb phosphorylation, total pRb, and 
phosphorylated pRb (ppRb).
Materials and Methods
Retinoblastoma specimens
A total of 245 unilateral retinoblastomas that had under-
gone complete screening for coding sequence and promoter 
region mutations in the RB1 gene were studied [4–6]. 
Ninety- four tumors were collected following enucleation 
at Wills Eye Hospital (CLS), Thomas Jefferson University, 
Philadelphia, PA. These specimens were submitted to the 
histopathology laboratory at Wills Eye Hospital (RCE) 
for routine processing, diagnosis, and descriptive analysis. 
Frozen or formalin- fixed paraffin- embedded samples were 
sent to the Genetics Diagnostic Laboratory (GDL), 
Perelman School of Medicine, University of Pennsylvania 
(AG), Philadelphia, PA for genetic testing. An additional 
151 cases of unilateral retinoblastoma were submitted to 
the GDL for genetic testing by 62 different sites in the 
US, Canada, Thailand, and Chile. Tumors used in this 
study were collected between 1982 and 2014. A small 
subset of 41 tumors was included in a previous study 
[7] and is indicated by an asterisk in Table S1. Pathology 
reports were available for 111 of the retinoblastoma sam-
ples (Table S2).
The Institutional Review Board of the University of 
Pennsylvania approved this research in accordance with 
an assurance filed with and approved by the U.S. 
Department of Health and Human Services. Since all 
patients were under the age of 18 years, written informed 
consent for use of tissues and data for research was 
obtained from a parent or legal guardian of all patients 
prior to genetic testing.
DNA isolation and screening of the RB1 gene
DNA was isolated from frozen and formalin- fixed, paraffin- 
embedded retinoblastoma specimens using Qiagen DNeasy 
Blood and Tissue kits following manufacturer’s protocols 
(Valencia, CA).
Mutation analysis of all 27 coding exons of the RB1 
gene, plus promoter and flanking intronic regions was 
performed by Sanger sequencing as previously described 
[4, 8]. Methylation status of the promoter region, estima-
tion of exonic copy number, and loss of heterozygosity 
(LOH) were carried out as previously described [4, 8]. 
Mutations were annotated based on Genbank accession 
L11910.1 and compared against the LOVD- RB1 database 
[9].
MYCN copy number determination and 
amplicon size
MYCN copy number was determined using an Applied 
Biosystems Taqman copy number assay (Hs00824796_cn, 
Life Technologies) using qPCR of tumor DNA following 
manufacturer’s protocols. To characterize genome- wide 
chromosomal changes and to determine the size of the 
MYCN amplicons, 38 retinoblastoma samples were geno-
typed using CytoScan HD SNP arrays following the manu-
facturer’s instruction (Affymetrix, Santa Clara, CA). Array 
specific CEL files were generated in GeneChip Command 
Console Software. The CytoScan HD array data were 
imported into Affymetrix Chromosome Analysis Suite 3.0 
(ChAS) software for analysis using filters for marker 
count = 50 and amplicon size = 100KB.
Immunohistochemistry
Routinely processed formalin- fixed and paraffin- 
embedded tumor sections were immumostained with 
antibodies against Skp2/p45 (SC- 7164, rabbit anti- human 
polyclonal [H- 435], Santa Cruz Biotechnology Inc, Dallas, 
TX), p27Kip1 (M 7203, mouse anti- human monoclonal, 
Dako, Carpinteria, CA), and pRb (4H1 mAB 9309, mouse 
anti- human, Cell Signaling, Danvers, MA) according to 
manufacturer’s protocols using an automated immu-
nostainer (Bond Max with Leica Bond Refine polymer, 
Leica Microsystems, Buffalo Grove, IL) with E1 (Skp2/
p45) and E2 (p27Kip1 and pRb) retrieval systems at dilu-
tions of 1:100, 1:200 and 1:300, respectively, followed 
by incubation at room temperature for one hour. Antibody 
to ppRb (S608) detects endogenous levels of pRb only 
when phosphorylated at Serine 608. Immunolocalization 
for ppRb was performed using a rabbit anti- human 
polyclonal antibody (92181, Cell Signaling, Danvers, 
MA) and a nonautomated protocol as previously 
described [10].
Statistical analysis
Statistical tests were carried out using the Fisher’s exact 
probability or chi- square test for contingency table analysis. 
Wilcoxon Mann–Whitney U- test or Kruskal–Wallis test 
was used to compare the ages of patients in the different 
mutation categories. All analyses were two- tailed and were 
carried out using IBM SPSS Statistics, version 23, vas-
sarstats (http://vassarstats.net/) or SISA (http://www. 
quantitativeskills.com/sisa/).
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Results
RB1 gene mutations and MYCN copy number 
changes in 245 unilateral retinoblastomas
The RB1 gene was scanned for the presence of mutations 
in the coding exons and in the gene promoter region, 
exonic copy number changes, and methylation status of 
the RB1 promoter sequence (Table 1 and Table S1). None 
of the tumors carried germline mutations. There were 
203 tumors with two mutations in RB1 (RB1−/−, 83%), 
29 with one (RB1+/−, 12%) and 13 with no detectable 
mutations (RB1+/+, 5%). A total of 435 somatic mutations 
were detected in 203 RB1−/− and 29 RB1+/− tumors. These 
included 199 (46%) point mutations, 136 (31%) instances 
of LOH, 57(13%) with promoter methylation, 36 (8%) 
exon deletions or duplications, and 7 (2%) complex rear-
rangements. There was no significant difference in the 
distribution of the types of mutations among tumors 
 carrying one or two mutations (P = 0.11, Table 1).
We next estimated the copy number status of the MYCN 
oncogene in the 245 retinoblastomas, which ranged from 
1 to 128 copies (Fig. 1). There were 227 (93%) tumors 
with less than 19 copies of MYCN (range 1–19), and 18 
(7.3%) with copy number greater than 29 (range 30–128), 
eight of which were RB1−/− (Fig. 1 and Table S1). There 
were no tumors with MYCN copy number between 19 
and 29.
Characteristic features of MYCN- amplified 
tumors
Of the 18 MYCN- amplified tumors, eight (44%) were 
RB1−/−, four (22%) were RB1+/−, and six (33%) were 
RB1+/+. Thus, twice as many tumors (66%) carried one 
or two RB1 mutations compared to 33% of tumors with 
no mutations. This difference in the number of MYCN- 
amplified retinoblastomas carrying two, one, or zero RB1 
mutations (eight, four, and six, respectively) compared 
to MYCN- low tumors (195, 25, and seven, respectively) 
was significant (P < 0.001, Table 1). It can be seen in 
Table 1, however, that there was no significant difference 
in the distribution of the five categories of RB1 mutations 
between the MYCN- amplified and MYCN- low tumors 
(P = 0.14), nor between MYCN- amplified and MYCN- low 
tumors within the RB1−/− (P = 0.36) or RB1+/− (P = 0.58) 
categories.
The age at which retinoblastoma was diagnosed was 
available for 239 cases (range = 0.5–136 months). There 
was no significant difference in the age of diagnosis and 
the presence of zero, one, or two RB1 gene mutations 
Table 1. RB1 mutation status in MYCN- amplified (MYCN- amp) and MYCN- low retinoblastomas.
RB1 mutation  
status
Total 
(frequency)
MYCN- 
amp 
(frequency)
MYCN- low 
(frequency)
RB1−/− RB1+/−
MYCN- 
amp MYCN- low
MYCN- 
amp
MYCN- 
low
N = 18 N = 227
RB1−/− 203 (83%) 8 (44%) 195 (86%)
RB1+/−   29 (12%) 4 (22%) 25 (11%)
RB1+/+   13 (5%) 6 (33%) 7 (3%)
P- value1 <0.001
Categories of  
mutations in  
RB1+/− and  
RB1−/− tumors
N = 435 
mutations
RB1−/− 
N = 406 
mutations
RB1+/− 
N = 29 
mutations N = 20 N = 415 N = 16 N = 390 N = 4 N = 25
Point  
mutations
199 (46%) 190 (47%)   9 (33%) 10 (50%) 189 (46%) 9 (50%) 181 (46%) 1 (25%)   8 (32%)
LOH 136 (31%) 125 (31%) 11 (41%)   5 (24%) 131 (32%) 4 (28%) 121 (31%) 1 (25%) 10 (40%)
Promoter  
methylation
  57 (13%)   52 (13%)   5 (18%)   2 (10%)   55 (13%) 2 (11%)   51 (13%) 1 (25%)   4 (16%)
Exonic  
deletions or 
duplications
  36 (8%)   34 (8%)   2 (7%)   1 (5%)   35 (8%) 1 (6%)   33 (9%) 0   2 (8%)
Complex 
 rearrangements
    7 (2%)     5 (2%)   2 (7%)   2 (10%)     5 (1%) 1 (6%)     4 (1%) 1 (25%)   1 (4%)
P- value1 0.11 0.14 0.36 0.58
LOH, loss of heterozygosity.
1P- values comparing number of tumors in RB1+/− with RB1−/−, and MYCN- amp with MYCN- low categories were determined by Fisher’s exact test 
(vassarstats) or Fisher 5*2 exact test (SISA).
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(P = 0.33, Table S1, compiled data not shown). The median 
age at diagnosis for 13 RB1+/+ was 15.0 months (mean ± 
SD =18.7 ± 17.5, range = 1–69), 24 months (25.9 ± 17.4, 
0.5–77) for 27 RB1+/−, and 24 months (26.7 ± 19.1, 1–136) 
for 199 RB1−/− (P = 0.12). However, the 18 MYCN- 
amplified tumors were diagnosed at a significantly earlier 
age: median of 9.5 months (16.1 ± 12.9, 1- 40) compared 
24.0 months (27.0 ± , 19.0, 0.5- 136) for 221 MYCN- low 
tumors (P = 0.012, Fig. 2).
Genome architecture, including whole genome chromo-
some copy number gains and losses, were determined for 
38 retinoblastomas: 14 MYCN- amplified and 24 MYCN- 
low tumors. Classic retinoblastoma- related chromosome 
copy number changes, including 1q gain, 6p gain, and 
16q loss [2,11–16], were observed in 14 (37%), 15 (40%), 
and seven (18%) tumors (Fig. 3A), respectively; however, 
there was no significant difference in the fraction of tumors 
with these copy number changes between MYCN- amplified 
and MYCN- low retinoblastomas (Table 2). Figure 3B 
depicts copy number changes in the MYCN region on 
chromosome 2, showing the length of the MYCN amplicon 
in 14 tumors with MYCN amplification. The size ranged 
between 1 and 5 MB in 13 tumors, and was 11 MB in 
one tumor. The size of the minimum overlapping region 
that included the MYCN gene was 948KB and included 
the MYCNOS (noncoding anti- sense RNA) gene and 
FAM49A exons 2- 11. Differences in copy number gains 
or losses for all other chromosomes were not 
significant.
Copy number gains of MDM4 and OTX2, and loss 
of BCOR in retinoblastoma have been reported previ-
ously [7, 12, 17]. In our collection of retinoblastomas, 
MDM4 and OTX2 copy number gains were found in 
16 (42%) and five (13%) of 38 retinoblastoma, respec-
tively. Loss of BCOR was seen in three of 34 tumors 
(7.9%) (Table 2); all three carried two or one RB1 muta-
tions. No significant association was found between the 
presence of these copy number gains or losses, and MYCN 
amplification. In the previous study of MYCN- amplified 
retinoblastoma, a lower frequency of copy number changes 
in four genes characteristic of retinoblastoma (KIF14, 
Figure 1. MYCN copy number in 245 retinoblastomas. Eighteen tumors carried MYCN copy number >29: 8 were RB1−/−, 4 were RB1+/−, and 6 were 
RB1+/+. The dashed horizontal red line indicates a MYCN copy number of 29. (See Table S1 for UPEN- RB- IDs for samples labeled 1- 245 in the Figure).
Figure 2. Age at diagnosis of 239 cases with retinoblastoma with and 
without MYCN amplification. Among the cases for whom age of onset 
was available, those with MYCN amplification developed retinoblastoma 
at a significantly younger age than those with MYCN- low tumors 
(Mann–Whitney U- test P = 0.012).
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Figure 3. Copy number changes on chromosomes 1, 2, 6, 13, and 16 in 38 retinoblastomas. Copy number gains (vertical blue bars), or losses (vertical 
red bars) were visualized using Affymetrix ChAS software. RB1 mutation status is indicated by −/−, +/-, and +/+ notation separately in the MYCN- 
amplified (- amp) and MYCN- low tumors. (A) Copy number changes on chromosomes 1, 6, 13, and 16 are indicated. The loss of the RB1 gene region 
is marked by a horizontal green line. (B) Chromosome 2 with the MYCN- amplified region is indicated by a horizontal dashed green line; blue bars 
indicate tumors with MYCN amplification. The figure on the right is an enlargement of the MYCN gene region, 2p24.3- p24.1, with the darker blue 
lines denoting the region of MYCN amplification. The vertical dashed green line indicates the location of the MYCN gene, and the vertical solid green 
lines denote the minimum amplified region (chr2:15,891,962- 16,839,842). Among the MYCN- low tumors, two had MYCN amplification of 3 which 
are indicated by lighter blue bars. The positions of two genes that map within the MYCN minimum amplified region, MYCNOS and FAM49, are 
marked.
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DEK, E2F3, and CDH11) was observed in RB1+/+ MYCN- 
amplified compared to RB1−/− tumors [2]. We found 
no significant difference in the number of copies of 
KIF14, DEK, and CDH11 between MYCN- amplified and 
MYCN- low tumors; however, there was a significant dif-
ference in copy number gains in E2F3 where a smaller 
fraction of MYCN- amplified tumors showed a gain (3/14, 
21%) compared to MYCN- low (14/24, 58%, P = 0.04) 
tumors (Table 2).
Pathology reports were available for 111 retinoblastomas 
and are summarized in Table S2: 12 were MYCN ampli-
fied and 99 were MYCN low. There was no significant 
association between the tumors carrying zero, one, or 
two RB1 mutations and the presence of high- risk features 
defined as invasion of the optic nerve to the level of the 
retrolamina, massive uveal/choroidal invasion and/or inva-
sion of the anterior chamber, iris or ciliary body (P = 0.73) 
[18, 19]. In addition, there was no significant difference 
between the degree of tumor differentiation and MYCN 
amplification status (P = 0.16) or tumors carrying zero, 
one, or two RB1 mutations (P = 0.77).
Among the 12 MYCN- amplified tumors with pathology 
reports, four (33%) had high- risk features compared to 
23 of 99 MYCN- low tumors (23%, P = 0.48). One of 
the four MYCN- amplified, high- risk tumors, (UPENN- 
RB- 175) was RB1+/+ and was diagnosed at 10 months, 
by which time the tumor had invaded both the ret-
rolaminar portion of the optic nerve and showed massive 
choroidal invasion. However, overall, the age of diagnosis 
was not significantly different between the four patients 
whose tumors had high- risk features and MYCN 
amplification and the 23 high- risk, but MYCN- low tumors 
(P = 0.16).
In terms of histological differentiation, 11 (92%) MYCN- 
amplified tumors were poorly differentiated consisting of 
neuroblastic cells and few, if any rosettes; one tumor was 
described as mixed with respect to differentiation (Table 
S2 and S3). This distribution of the degree of differentia-
tion was not significantly different from that found in 
MYCN- low retinoblastoma: 63 (68%) undifferentiated/
poorly differentiated, 21 (23%) well or moderately well 
differentiated with numerous Flexner–Wintersteiner 
rosettes, and seven (7.6%) with mixed status (P = 0.16, 
compiled data not shown).
Immunohistochemical staining pattern
We compared the relative levels of expression of SKP2, 
p27, pRb, and ppRb proteins in four MYCN- amplified 
and one MYCN- low retinoblastomas by immunohisto-
chemistry (IHC) staining of tumor sections with antibodies 
specific for these proteins (Table 3 and Fig. 4, Figure S1 
and Table S4).
Staining with anti- SKP2 antibody was essentially nega-
tive in all five retinoblastomas, although a few scattered 
positive cells were present in the four MYCN- amplified 
tumors (Fig. S1, panels A,C,E,G,H) and Table S4). The 
p27 staining pattern in UPEN- RB- 175 was faint and 
diffuse (Fig. S1 B; RB1+/+), while in UPEN- RB- 93 and 
UPEN- RB- 40 (Fig. S1, D,F; both RB1+/−), it was patchy 
and focally strong, especially in UPEN- RB- 40. Over 90% 
of tumor cells in UPEN- RB- 201 (RB1−/−) were strongly 
Table 2. Chromosome and gene gains and losses in 38 retinoblastomas assessed using Affymetrix Cytoscan HD SNP arrays and analyzed with ChAS 
software.
Location1
Number with chromosome gain 
or loss (percent of total)
MYCN- amplified 
(CN>29) MYCN- low
Total N = 38 N = 14 N = 24 P- value2
Chromosome gain or loss
1q gain 14 (37%) 4 (29%) 10 (42%) 0.50
6p gain 15 (40%) 3 (21%) 12 (50%) 0.10
16q loss 7 (18%) 1 (7.1%) 6 (25%) 0.23
Gene gain or loss
 MDM4 gain3 Chr1:204,485,507- 204,527,248 16 (42%) 6 (43%) 10 (42%) 1.00
 OTX2 gain3 Chr14:57,267,425- 57,272,381 5 (13%) 2 (14%) 3 (12%) 1.00
 BCOR loss3 ChrX:39,910,499- 39,956,719 3 (7.8%) 2 (14%) 1 (4.2%) 0.54
 KIF14 gain4 Chr1:200,520,625- 200,589,862 11 (29%) 3 (21%) 8 (33%) 0.49
 DEK gain4 Chr6:18,224,400- 18,264,799 18 (47%) 4 (29%) 14 (58%) 0.10
 E2F3 gain4 Chr6:20,402,137- 20,493,945 17 (45%) 3 (21%) 14 (58%) 0.04
 CDH11 loss4 Chr16:64,980,683- 65,155,919 7 (18%) 1 (7.1%) 6 (25%) 0.23
1GRCh37/hg19 assembly.
2Fisher’s exact, two- tailed, P- value (http://vassarstats.net/tab 2 × 2.html).
3McEvoy, et al.[7]
4Rushlow, et al.[2]
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Figure 4. Expression of pRb and ppRb in the normal retina and in the tumor of four MYCN- amplified and one MYCN- low retinoblastoma identified 
by immunostaining with antibodies against the two proteins. The anti- ppRb stain is specifically targeted against phosphorylated S608. In the retina 
images, the ONL is positioned on the left and the INL on the right. A moderate level of pRb and ppRb reactivity is seen in less than half of the cells in 
both the ONL and INL of MYCN- amplified tumors UPEN- RB- 175 (RB1+/+, A, C) and the two RB1+/− tumors, UPEN- RB- 93 (E, G) and UPEN- RB- 40 (I, K). 
Most cells in both retinal layers were strongly positive for pRb (M), but not ppRb (P) in UPEN- RB- 201 (MYCN- amplified, but RB1+/−). The INL of UPEN- 
RB- 112 (MYCN- low, RB1−/−) shows weak reactivity for pRb in about 25% of cells and even fewer are positive for ppRb, the ONL is essentially negative 
for both proteins (S, U). The MYCN- amplified tumors with zero (B) or one RB1 mutation (F, J) are poorly differentiated with most cells strongly stained 
with pRb. Many cells are also positive with ppRb antibody (D, H, L) but the staining tends to be weaker. The regions of UPEN- RN- 201 (MYCN- amp 
and RB1−/−) that are well differentiated with many FW rosettes show very little reactivity with pRb or ppRb (O, R), while scattered positive cells are 
present in the poorly differentiated regions (N, Q). Similarly, the well- differentiated RB1−/−, but MYCN- low tumor, UPEN- RB- 112, was essentially 
negative for pRb and ppRb (T, V). Abbreviations: inner (INL) and outer (ONL) nuclear layer of the retina; TRosettes, region of tumor containing numerous 
rosettes; TPD, poorly differentiated region of the tumor. (Original magnification ×40).
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positive (Fig. S1, I,J). UPEN- RB- 112 (MYCN-low, RB1−/−) 
was negative for SKP2 (Fig. S1, K), but showed very 
weak reactivity for p27 in some areas (Fig. S1, L) 
(Table S4).
The histopathological features, as well as pRb and ppRb 
(Ser608) IHC staining pattern in five retinoblastoma tumor 
sections and matched normal retina (defined as retinal 
tissue not in proximity to the tumor) are visualized in 
Figure 4 and described in Table 3. About 25–50% of 
cells in the inner (INL) and outer (ONL) nuclear layers 
of the normal retina were moderately to strongly stained 
with both pRb and ppRb antibodies in the MYCN- amplified 
tumors UPEN- RB- 175 (Fig. 4, panels A,C), UPEN- RB- 93 
(Fig. 4E,G), and UPEN- RB- 40 (Fig. 4I,K) carrying zero 
or one RB1 mutations. This would indicate that the pRb 
protein that is expressed is phosphorylated. Over 90% of 
cells in the INL and ONL of UPEN- RB- 201 (MYCN- 
amplified but RB1−/−) were strongly positive for pRb; 
however, only about 70% of cells in the INL (Fig. 4M), 
and less than 5% in the ONL were ppRb immunoreactive 
(Fig. 4P). The INL of UPEN- RB- 112 (MYCN- low and 
RB1−/−) had about 25% pRb- positive cells, but only very 
few ppRb- positive cells (Fig. 4S), and the ONL was essen-
tially negative for both proteins (Fig. 4U) (Table 3).
Tumor sections of UPEN- RB- 175 (MYCN- amplified, 
RB1+/+) stained strongly for pRb and ppRb (Fig. 4B,D), 
while the two MYCN- amplified RB1+/− stained strongly 
with pRb antibody (Fig. 4F,J), but showed weaker staining 
of fewer cells with ppRb antibody (Fig. 4H,L). Interestingly, 
the well- differentiated region of UPEN- RB- 201 with many 
Flexner–Wintersteiner (FW) rosettes was mostly negative 
for both pRb and ppRb (Fig. 4O,R); however, the poorly 
differentiated section had scattered positive cells 
(Fig. 4N,Q). UPEN- RB- 112 tumor was well differentiated 
with many FW rosettes and essentially negative for pRb 
and ppRb (Table S3 and Fig. 4). In all tumors, the immu-
noreactive pRb and ppRb proteins were primarily con-
centrated in the nucleus with very little staining of the 
cytoplasm.
Figure 5 shows staining of the retinal section that seeds 
the retinoblastoma in two tumors with MYCN amplifica-
tion, UPEN- RB- 93 and UPEN- RB- 40. With respect to pRb 
expression, there are relatively few scattered positive cells 
in both the ONL and INL; however, numerous darkly 
stained tumor cells can be seen originating from the adja-
cent weakly stained INL. Both tumors carry only one 
RB1 mutation; so, some expression of pRb is to be expected. 
In contrast, there is very little expression of ppRb in the 
INL of either tumor but significant expression is seen in 
the adjacent tumor section for both tumors. These results 
appear to show that tumor cells expressing both pRb and 
ppRb proteins may originate in the retinal INL, and not 
from the ONL, However, it is also possible that these 
cells may originate elsewhere and migrate into the INL, 
or preferentially invade the INL at the edges of a large 
tumor.
Figure 5. Transitional zone of the retina in two MYCN- amplified, RB1+/− retinoblastomas, UPEN- RB- 93 and UPEN- RB- 40, immumostained with 
antibodies against pRb (A, C) and ppRb (B, D). The images show tumor cells migrating from the INL of the retina. The majority of cells in the region 
of the expanding tumors show moderate- to- strong reactivity for both pRb and ppRb compared to the adjacent INL which appears to be seeding the 
tumor, but where fewer cells are pRb- positive and are mostly negative for ppRb. The staining pattern in the ONL of both pRb and ppRb appears 
comparable in this transition zone. Abbreviations: tumor (T), inner (INL) and outer (ONL) nuclear layer of the retina. (Original magnification ×40).
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Discussion
Rushlow et al. reported a class of novel RB1+/+ retino-
blastoma with no genetic mutations in RB1, but having 
a high level of MYCN amplification (>29 copies) [2]. 
This led to the hypothesis that high level MYCN ampli-
fication is sufficient for initiation of tumorigenesis of 
RB1+/+ retinoblastoma. In this manuscript, we investigated 
the characteristics of MYCN- amplified sporadic unilateral 
retinoblastoma and the mechanisms of inactivation of the 
RB1 gene in these tumors.
Newly diagnosed, sporadic unilateral retinoblastoma is 
caused by somatic mutations in over 80% of cases, and 
by low penetrance germline mutations in the RB1 gene 
in 15% of cases [4]. The sensitivity of mutation detection 
in coding sequences of RB1 is high, around 94% but not 
100% [4]. The current methods of mutation screening 
of RB1 are limited to the promoter region, coding exons, 
and immediate flanking intronic regions, but not the entire 
introns which are known to harbor mutations [20, 21] 
and/or rearrangements including chromothripsis [7] that 
can also inactivate the RB1 locus. Thus, based on current 
sensitivity of DNA- based genetic testing, the presence of 
a subset of retinoblastoma without a detectable mutation 
in the RB1 gene is not unexpected. Assuming a sensitivity 
for finding a coding sequence RB1 mutation to be 94% 
[4], one would expect to observe only one wild- type 
RB1+/+ retinoblastoma among the 245 tested. However, 
we identified 13 (5.3%, P < 0.001) tumors without any 
RB1 mutation.
We identified 18 of 245 retinoblastomas (7%) with a 
high MYCN copy number between 29 and 110 copies 
(Fig. 1). Of these, eight tumors carried two mutations in 
RB1, four were RB1+/−, and six were RB1+/+. This finding 
that 44% of MYCN- amplified tumors carried two RB1 
mutations directly contrasts the observation by Rushlow 
et al. [2] who found no retinoblastomas with MYCN 
amplification among 93 tumors with two mutations in 
RB1 (RB1−/−). Further investigations into alternate mecha-
nisms of inactivation of the RB1 gene product demonstrated 
phosphorylation of pRb at S608 in tumors without coding 
sequence mutations in one or both alleles of RB1 which 
is consistent with the observation that phosphorylation 
is the most common mechanism of pRb inactivation in 
most known cancers [22, 23].
MYCN amplification in retinoblastoma was first 
described by Lee et al. [24] showing that the MYCN gene 
was amplified 10–200- fold in two primary retinoblastomas 
and in the Y79 cell line, but not in fibroblasts. Subsequently, 
Mairal et al. [14] assessed MYCN amplification karyotypi-
cally as double- minute chromosomes and by PCR in four 
of 20 primary retinoblastomas. Further studies in a geneti-
cally engineered mouse model of human retinoblastoma 
demonstrated a 6–400- fold amplification of MYCN in 
three of 16 aggressive retinoblastomas [25].
Amplification of MYCN has been described in about 
20% of neuroblastoma where it identifies a highly aggres-
sive subtype of the tumor [26, 27]. In contrast, Lillington 
[28] found in a study of 25 primary retinoblastomas, 
that three tumors with MYCN amplification (>30 fold) 
were not associated with high- risk histological features. 
In our series, retinoblastoma cases with high MYCN copy 
number were associated with an earlier age of onset that 
was significantly different from that of retinoblastoma 
without MYCN amplification (Fig. 2). However, there was 
no difference in the presence of high- risk features between 
the two groups of tumors with and without the 
amplification.
In many cancers, the regulation of pRb becomes unbal-
anced, and elevated cyclin- dependent kinase (CDK) activity 
prevents pRb from being an effective brake on cell cycle 
control. One of the potent CDK inhibitors is p27, a pro-
tein which is degraded by the protein, SKP2. In addition, 
SKP2 is a known target of MYCN amplification in neu-
roblastoma [29]. The IHC staining results in our tumors 
indicate the absence of SKP2 protein in any significant 
amount and could signal high expression of p27 protein. 
However, the weak p27 immunoreactivity suggests that 
it is expressed in low levels in all MYCN- amplified tumors, 
except the RB1−/− tumor, UPEN- RB- 201, where it is highly 
expressed in both well and poorly differentiated areas of 
the tumor (Fig. S1, I, and J). Further comparison of p27 
expression in UPEN- RB- 201 and UPEN- RB- 112 which is 
also RB1−/−, but MYCN- low suggests that p27 is up- 
regulated in the presence of MYCN amplification, but 
not in MYCN- low tumors in the absence of pRb. In 
essence, these observations rule out the activation of the 
MYCN- SKP2- p27 axis in three out of four MYCN- amplified 
retinoblastomas. Since it is known that p27 is degraded 
upon progression into S- phase when both pRb and p27 
are phosphorylated [29], we investigated the phosphoryla-
tion status of pRb.
Alterations in pRb phosphorylation during late G1 phase 
allow the activation of E2F- dependent transcription that 
drives the cell cycle and is needed for DNA replication. 
It has been shown that the alteration in the structure of 
pRb by phosphorylation at multiple residues, including 
S608/S612 [30, 31] causes specific conformational changes 
and are sufficient for inhibition of interaction with the 
transactivating domain of E2F, while phosphorylation at 
S795 inhibits binding to the marked box (MB) domain 
of E2F1 [29].
The observation that pRb is phosphorylated at S608 
and/or S795 residue in the MYCN- amplified retinoblastoma 
provides an important insight into how retinoblastoma 
develops without mutational knock- out of the RB1 gene 
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which has conventionally been known as the rate- limiting 
step in this process [1]. In a recent paper, Liu et al. [32] 
have shown that following pRb loss, there is evidence for 
Myc- dependent E2f3 accumulation and “rampant cell 
proliferation”. In commenting on these findings, Osorio 
[33] suggests that when functional pRb is not present in 
the cell, factors such as MYCN and E2Fs are “repurposed” 
resulting in unregulated cell proliferation.
Thus, in conclusion, in our series of 18 MYCN- amplified 
retinoblastomas, 12 carry inactivating coding sequence 
mutations in the RB1 gene and six do not. While inac-
tivation of RB1 by mutations has been classically associated 
with retinoblastoma, deregulation of the pRb pathway is 
very common in most types of human cancer [23, 24]. 
Very few of these cancers carry mutations in the RB1 
gene, and pRb, is inactivated by phosphorylation in these 
nonretinoblastoma cancers. Similarly, in the retinoblastoma 
without coding sequence mutations, pRb, is inactivated 
by phosphorylation at various sites, including S608 and 
S795, which are two of the key residues that determine 
the interaction with E2F family of transcription factors 
[34]. Hence, pRb inactivation, through mutation, phos-
phorylation or some other as yet unknown mechanism, 
is likely to be the initiating event in retinoblastoma tumo-
rigenesis with or without MYCN amplification.
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